HIV antigen variability in ARC/AIDS
- PMID: 1910082
HIV antigen variability in ARC/AIDS
Abstract
To define the natural variability of human immunodeficiency virus p24 antigen (HIV Ag) over time in untreated HIV-infected patients, we analyzed the percentage change of serum HIV Ag in 40 antigenemic ARC/AIDS subjects receiving placebo in a 24 week clinical trial. When grouped by month of observation, no differences in HIV Ag change were seen among all five 1 month observation periods (p greater than 0.4). After all 105 monthly changes (median of 3 per subject) were pooled, the mean monthly HIV Ag change was 0% change (standard deviation: 77% increase, 44% decrease). Furthermore, HIV Ag changes did not differ among all lengths of observation (from 1 to 5 months using all possible pairwise combinations of HIV Ag levels, p greater than 0.4). CD4 T-cell changes over the whole study did not correlate with HIV Ag changes over the same period. Knowledge of this broad HIV Ag variability should be useful in calculating sample size and in choosing categorical responses unlikely to occur spontaneously in clinical trials of antiviral agents where HIV Ag changes are used as surrogate markers of efficacy.
Similar articles
-
Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.BMJ. 1991 Jan 12;302(6768):73-8. doi: 10.1136/bmj.302.6768.73. BMJ. 1991. PMID: 1671651 Free PMC article.
-
Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.N Engl J Med. 1990 Apr 5;322(14):941-9. doi: 10.1056/NEJM199004053221401. N Engl J Med. 1990. PMID: 1969115 Clinical Trial.
-
Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial.Arch Intern Med. 1988 Oct;148(10):2151-3. Arch Intern Med. 1988. PMID: 3263098 Clinical Trial.
-
Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus.J Acquir Immune Defic Syndr (1988). 1990;3(8):743-6. J Acquir Immune Defic Syndr (1988). 1990. PMID: 2114476
-
Safety and tolerance of dideoxycytidine as a single agent. Results of early-phase studies in patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex. Study Group of the AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.Am J Med. 1990 May 21;88(5B):11S-15S. doi: 10.1016/0002-9343(90)90415-a. Am J Med. 1990. PMID: 2159703 Review.
Cited by
-
Pharmacokinetics, toxicity, and activity of intravenous dextran sulfate in human immunodeficiency virus infection.Antimicrob Agents Chemother. 1991 Dec;35(12):2544-50. doi: 10.1128/AAC.35.12.2544. Antimicrob Agents Chemother. 1991. PMID: 1810188 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials